Summary
Four brand names dominate talk about weight-loss medicines, but they contain only two drugs. Ozempic and Wegovy are both semaglutide, and Mounjaro and Zepbound are both tirzepatide. In each pair, the Food and Drug Administration approved one brand for type 2 diabetes and one for long-term weight management, and several now have other approved uses as well. I compare them and explain why the nutrition around the medicine matters as much as the choice of drug.
- Semaglutide is a GLP-1 medicine. It copies a gut hormone released after eating, which slows how fast the stomach empties, quiets appetite and improves blood sugar. Tirzepatide also acts on a second hormone pathway, called GIP.
- In the makers’ main trials, published in 2021 and 2022, average weight loss was about 15 percent of body weight on semaglutide. On tirzepatide at the top dose it was about 20 to 21 percent. These are averages, not promises.
- All four come as weekly injections. Semaglutide is also approved as a daily tablet under both of its names. Doses rise slowly over months. Common side effects are alike: nausea, constipation, diarrhea and less appetite, generally strongest after a dose increase.
- The nutrition priorities are nearly the same on all four: enough protein (about 1.6 grams per kilogram of ideal body weight a day), resistance training to protect muscle, managing stomach side effects, and a plan for maintenance.
- I do not prescribe these medicines. Choosing one is your prescriber’s decision. This is general education, not medical advice.
Summary added 2 October 2026.
The names multiply faster than the medications behind them. Four brands, Ozempic, Wegovy, Mounjaro, and Zepbound, dominate the weight-loss conversation, but they trace back to only two molecules. Ozempic and Wegovy are the same drug. Mounjaro and Zepbound are the same drug. Once you see that, the whole landscape gets simpler. Here is how the four compare, from a dietitian who works with patients on all of them, and what actually separates a good result from a disappointing one.
To be clear at the outset: I do not prescribe these medications, and this is general education, not medical advice. Which medication is right for you is a decision for your prescribing clinician, based on your health history, your insurance coverage, and your goals. My job begins where the prescription leaves off, with the nutrition that protects your muscle and makes the results last.
The short version
Ozempic and Wegovy are both semaglutide (a GLP-1 receptor agonist). Mounjaro and Zepbound are both tirzepatide (a dual GIP and GLP-1 agonist). Within each pair, the main difference is the FDA-approved use and the brand name: the diabetes version and the weight-management version, and several now carry other approved uses as well (see the table). All four come as once-weekly injections, and semaglutide is also approved as a once-daily tablet under both the Ozempic and Wegovy names. In clinical trials, semaglutide averaged about 15 percent body-weight loss at the 2.4 mg dose and tirzepatide about 20 to 21 percent at the top dose. The medication is only half the equation; nutrition and muscle protection are the other half.
The comparison, side by side
The table below lays out the four medications on the dimensions patients ask about most. All weight-loss figures are averages from the manufacturers' pivotal clinical trials, not promises for any individual, and are rounded for readability.
| Ozempic | Wegovy | Mounjaro | Zepbound | |
|---|---|---|---|---|
| Active ingredient | Semaglutide | Semaglutide | Tirzepatide | Tirzepatide |
| Drug class / mechanism | GLP-1 receptor agonist (single incretin pathway) | Dual GIP and GLP-1 receptor agonist (two incretin pathways) | ||
| FDA-approved use | Type 2 diabetes; also lowers the risk of heart attack, stroke and cardiovascular death, and of kidney decline, in some adults with type 2 diabetes | Chronic weight management; also lowers the risk of heart attack, stroke and cardiovascular death in adults with heart disease and obesity or overweight, and treats MASH, a fatty liver disease with liver scarring (injection only) | Type 2 diabetes in adults and children 10 and older; also lowers cardiovascular risk in some adults with type 2 diabetes (added August 2026) | Chronic weight management; also moderate to severe obstructive sleep apnea in adults with obesity |
| Typical trial weight loss | ~15% of body weight (STEP program, at higher weight-management doses)[1] | ~20–21% of body weight at the top dose (SURMOUNT program)[2] | ||
| Dosing | Once-weekly injection, titrated up gradually over months; Ozempic and Wegovy also come as once-daily tablets | Once-weekly injection, titrated up gradually over months | ||
| Common side effects | Nausea, constipation, diarrhea, reduced appetite; generally strongest after a dose increase and easing over time | |||
Trial figures are group averages from the manufacturers' pivotal studies, rounded, and reported for context in clinical trials. Individual results vary. This table is educational and does not recommend any medication. Approved uses as listed on the FDA labels on 2 October 2026.
What the two molecules actually are
Semaglutide (Ozempic and Wegovy) is a GLP-1 receptor agonist. It mimics a gut hormone your body releases after eating, which slows stomach emptying, quiets appetite, and improves blood-sugar control. Ozempic is the version approved for type 2 diabetes; Wegovy is the same molecule approved, at higher doses, for chronic weight management. If you have been comparing an "Ozempic diet" with a "Wegovy diet," there is nothing to reconcile: it is one drug and one nutrition approach.
Tirzepatide (Mounjaro and Zepbound) goes a step further. It is a dual agonist, acting on both the GLP-1 receptor and a second incretin receptor called GIP. In clinical trials, that dual mechanism translated into larger average weight loss than semaglutide. Mounjaro is approved for type 2 diabetes; Zepbound is the same molecule approved for weight management. Same drug, same diet, as covered in the tirzepatide-specific eating guide.
Bigger weight loss raises the nutrition stakes
The headline advantage of tirzepatide, more average weight loss, is exactly why nutrition matters more, not less. The more total weight you lose, the more muscle is on the line if protein and resistance training are inadequate. The medication that gives the best scale result also carries the greatest opportunity to lose lean mass. See how much of GLP-1 weight loss is lean mass.
Where the differences stop mattering
Patients spend a great deal of energy choosing between these medications, and that choice does matter. But once the prescription is written, the four demand almost identical things of you nutritionally. Every one of them works by reducing how much you want to eat. That is the therapeutic point, and also the risk: a smaller appetite makes it easy to fall short on protein, lose muscle alongside fat, and struggle with the same gastrointestinal side effects regardless of brand.
So whichever medication you and your prescriber land on, the nutrition playbook converges on the same four priorities:
- Hit your protein target. About 1.6 grams per kilogram of ideal body weight per day, spread across the day, to protect muscle while you lose fat. On a suppressed appetite that takes real strategy. (the 2x protein rule.)
- Protect lean mass with resistance training. Protein supplies the raw material; lifting is the signal that tells your body to keep the muscle. This is the half food alone cannot do.
- Manage the GI side effects so you can keep eating. Nausea, early fullness, and constipation are common across all four and spike after dose increases. Eating well through them is what keeps a good plan on track.
- Plan for maintenance from the start. What happens if the medication stops is decided by the muscle you protected and the habits you built while on it. (maintaining weight after a GLP-1.)
"Choosing the medication is your prescriber's job. Making it work, and making it last, is where nutrition earns its place."
So which one is "best"?
It is the wrong question, or at least an incomplete one. On trial averages, tirzepatide produced more weight loss than semaglutide, but averages are not individuals. The "best" medication is the one your prescriber judges to fit your health history, that your insurance will actually cover, that you tolerate well enough to stay on, and that you pair with the nutrition and training to protect what matters. A medication with a slightly lower trial average, used consistently and supported properly, will outperform a stronger one abandoned after a rough week or undermined by muscle loss.
That is the honest dietitian's answer: the differences between these drugs are real and worth discussing with your clinician, but they are not where most results are won or lost. The everyday nutrition around the medication is.
Frequently asked questions
Are Ozempic and Wegovy the same drug?
Yes. Ozempic and Wegovy are the same molecule, semaglutide, a GLP-1 receptor agonist. They are marketed under different names for different FDA-approved uses: Ozempic is approved for type 2 diabetes, and Wegovy is approved for chronic weight management, with other approved uses listed in the table above. The higher doses used for weight management are why Wegovy exists as a separate brand.
Is Mounjaro or Ozempic better for weight loss?
In clinical trials, tirzepatide (the molecule in Mounjaro and Zepbound) produced greater average weight loss than semaglutide (the molecule in Ozempic and Wegovy): roughly 20 to 21 percent of body weight at the top dose in the SURMOUNT program versus roughly 15 percent for semaglutide in the STEP program. That does not make one universally better for a given person. Which medication is appropriate depends on your health history, tolerance, insurance coverage, and goals, and that decision belongs to your prescribing clinician.
What is the difference between Mounjaro and Zepbound?
There is no difference in the medication itself. Mounjaro and Zepbound are both tirzepatide, a dual GIP and GLP-1 receptor agonist given as a once-weekly injection. The names reflect their FDA-approved uses: Mounjaro is approved for type 2 diabetes, and Zepbound is approved for chronic weight management and for obstructive sleep apnea in adults with obesity. The nutrition approach is identical for both.
Do I need a dietitian while on a GLP-1?
A dietitian is not required to be prescribed a GLP-1, but nutrition is what determines the quality of your results. These medications work by reducing appetite, which makes it easy to under-eat protein and lose muscle along with fat. A dietitian helps you hit protein targets, manage GI side effects so you can keep eating, protect lean mass with the right habits, and build a plan to prevent regain if the medication is stopped. The prescriber manages the drug; the dietitian manages the nutrition around it.
Which GLP-1 has fewer side effects?
All of these medications share the same category of side effects, mostly gastrointestinal: nausea, constipation, diarrhea, and reduced appetite, which are usually strongest after a dose increase and tend to ease with time. Clinical trials have not established one as clearly gentler for everyone, and tolerability varies widely from person to person. Slow dose titration and a deliberate eating strategy influence how you feel more than the specific brand does.
Are these medications interchangeable?
No. Even though Ozempic and Wegovy contain the same molecule, and Mounjaro and Zepbound contain the same molecule, each brand is approved for different uses, Ozempic and Wegovy reach different top doses, and they are not automatically swapped for one another. Semaglutide and tirzepatide are entirely different molecules with different mechanisms. Any change between medications or doses is a clinical decision made by your prescriber based on your health, response, and coverage.
Where a dietitian fits
Your prescriber chooses the medication and manages the dose. What many people do not get is anyone managing the nutrition that protects their muscle, keeps the side effects livable, and makes the results hold if the drug stops. Building that plan, protein, side-effect strategy, resistance training, and a maintenance roadmap, around your labs and your life, is exactly what I offer at Vitae Arete, whichever of these four medications you are on.
On a GLP-1, or deciding? Let's build the nutrition half.
Whichever medication you and your prescriber choose, a plan built to protect your muscle and make the loss last is what turns it into a lasting result.
Book a 15-min discovery callThis article is general nutrition education, not individualized medical or nutrition advice, and it does not create a dietitian–client relationship. Semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), the choice of medication, and any side effects should be managed with your prescribing clinician. See the full disclaimer.
Correction, 2 October 2026. A review of my past posts found that this comparison was out of date on the medicines’ approved forms and uses. That was already true when it was published on 1 July 2026. It said all four are once-weekly injections. That was incomplete. Semaglutide had also been approved as a once-daily tablet under both names. Wegovy tablets were approved on 22 December 2025, and Ozempic tablets on 30 January 2026. It said the only difference within each pair is the approved use, diabetes or weight management. That was also incomplete. Several brands had other approved uses: heart risk reduction for Wegovy and Ozempic, kidney risk reduction for Ozempic, a fatty liver disease for Wegovy, and sleep apnea for Zepbound. Mounjaro added a heart risk use on 27 August 2026, after publication. The table, the summary and the answers on approved uses now follow the Food and Drug Administration labels as of 2 October 2026. The comparison of the two molecules is unchanged. Smaller changes were also made: one answer no longer says that Mounjaro and Zepbound are prescribed at different doses, since they come in the same doses, the protein target now reads about 1.6 grams per kilogram of ideal body weight, and a sentence about my practice was reworded.